Retroscreen Virology Group PLC Result of AGM (7358H)
21 Mai 2014 - 5:00PM
UK Regulatory
TIDMRVG
RNS Number : 7358H
Retroscreen Virology Group PLC
21 May 2014
For immediate release 4.00pm: 21 May 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
RESULT OF ANNUAL GENERAL MEETING
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce that all
resolutions proposed at its Annual General Meeting, held at 10am on
21 May 2014, were duly passed.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness because the Company
believes that the best way to understand human disease is by
studying it in humans, not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGSEMFLFFLSEII
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024